Poxel generated consolidated revenue of €5 millions1 for the year ended 31 December 2025, compared with €6.6 million in the corresponding period in 2024, which included a milestone payment of ¥500 ...
Gross sales of TWYMEEG ® in Japan continued to accelerate, increasing by 15.0% in the fourth quarter of 2025 (October–December) compared with the previous quarter, and by 40% compared with the fourth ...
LYON, France, February 16, 2026--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic ...
LYON, France, January 30, 2026--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic ...
*Net of R&D tax credit. Poxel generated revenue of €2.183 million in the first half of 2025, compared to €1.162 million during the same period in 2024, corresponding mainly to ¥345 million in ...
LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases ...
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic ...
LYON, France--(BUSINESS WIRE)-- Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases ...
Following the non-adoption of key financial delegations at the Combined General Meeting held on February 11, 2025, the Company is facing an uncertain and adverse situation regarding the continuation ...
POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, ...
POXEL SA FRANCE (PXXLF) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...
Results from a phase 2 trial show PXL770 yielded consistently greater responses in high-risk patients with comorbid nonalcoholic steatohepatitis (NASH) and type 2 diabetes (T2D) compared with placebo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results